Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

465
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
465
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

103
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
103
Lipid Digestion01:06

Lipid Digestion

89.1K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
89.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.

European heart journal·2026
Same author

Homozygous familial hypercholesterolaemia: insights from the Global HICC Registry.

European heart journal·2026
Same author

Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia.

European journal of preventive cardiology·2026
Same author

Cascade screening for elevated Lp(a) in relatives of children who visited the pediatric lipid clinic: yield of daily clinical practice.

European journal of preventive cardiology·2026
Same author

Statin-associated symptoms and statin intolerance in children with familial hypercholesterolemia: Insights from 15 years of clinical practice.

Atherosclerosis·2026
Same author

Baseline characteristics and response to evinacumab in females and males with homozygous familial hypercholesterolemia in the ELIPSE OLE study.

American journal of preventive cardiology·2026

Related Experiment Video

Updated: May 12, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.2K

The Brussels International Declaration on Lipoprotein(a) Testing and Management.

Florian Kronenberg1, Nicola Bedlington2, Zanfina Ademi3

  • 1Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria; Lp(a) International Task Force, FH Europe Foundation, Amsterdam, Netherlands.

Atherosclerosis
|May 8, 2025
PubMed
Summary

High lipoprotein(a) [Lp(a)] is a major cardiovascular risk, yet testing is rare. The Brussels Declaration urges integrating Lp(a) testing into health plans for early detection and management.

Keywords:
Cardiovascular riskCardiovascular risk evaluationLipoprotein(a)Patient engagementScreening

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

10.9K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.9K

Related Experiment Videos

Last Updated: May 12, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.2K
Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

10.9K
Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

3.9K

Area of Science:

  • Cardiovascular Medicine
  • Public Health Policy
  • Genetic Risk Factors

Background:

  • Elevated lipoprotein(a) [Lp(a)] is a significant, independent, and causal risk factor for cardiovascular disease.
  • Current Lp(a) testing rates are critically low (1-2%), despite 20% of the population having elevated levels.
  • This disparity highlights a gap in cardiovascular risk assessment and preventative strategies.

Purpose of the Study:

  • To address the low rates of lipoprotein(a) [Lp(a)] testing and management globally.
  • To advocate for policy changes and increased awareness regarding Lp(a) as a cardiovascular risk factor.
  • To foster a coordinated international effort for Lp(a) testing and management.

Main Methods:

  • Convening the Lp(a) Global Summit in Brussels, Belgium (March 24-25, 2025).
  • Co-creation of the Brussels International Declaration on Lp(a) Testing and Management by the Lp(a) International Task Force and global leaders.
  • Collaboration with scientific organizations, patient advocacy groups, and policymakers.

Main Results:

  • The Brussels Declaration outlines five key calls to action for improving Lp(a) testing and management.
  • These include integrating Lp(a) into cardiovascular health plans, investing in targeted programs, mandating systematic testing, incorporating results into risk assessments, and enhancing education.
  • The declaration emphasizes the cost-saving potential of proactive Lp(a) management.

Conclusions:

  • Systematic, reimbursed, and lifelong lipoprotein(a) [Lp(a)] testing is essential for cardiovascular disease prevention.
  • Policy integration, investment, and education are crucial for effective Lp(a) management.
  • Addressing elevated Lp(a) levels can significantly reduce cardiovascular risk and healthcare costs.